Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results
TA Yap, E Fontana, EK Lee, DR Spigel, M Højgaard… - Nature medicine, 2023 - nature.com
Predictive biomarkers of response are essential to effectively guide targeted cancer
treatment. Ataxia telangiectasia and Rad3-related kinase inhibitors (ATRi) have been shown …
treatment. Ataxia telangiectasia and Rad3-related kinase inhibitors (ATRi) have been shown …
First-in-human trial of the oral ataxia telangiectasia and RAD3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors
TA Yap, DSP Tan, A Terbuch, R Caldwell, C Guo… - Cancer discovery, 2021 - AACR
Targeting the ataxia telangiectasia and RAD3-related (ATR) enzyme represents a promising
anticancer strategy for tumors with DNA damage response (DDR) defects and replication …
anticancer strategy for tumors with DNA damage response (DDR) defects and replication …
Guiding ATR and PARP inhibitor combinations with chemogenomic screens
M Zimmermann, C Bernier, B Kaiser, S Fournier, L Li… - Cell Reports, 2022 - cell.com
Combinations of ataxia telangiectasia-and Rad3-related kinase inhibitors (ATRis) and poly
(ADP-ribose) polymerase inhibitors (PARPis) synergistically kill tumor cells through …
(ADP-ribose) polymerase inhibitors (PARPis) synergistically kill tumor cells through …
Loss of cyclin C or CDK8 provides ATR inhibitor resistance by suppressing transcription-associated replication stress
RL Lloyd, V Urban, F Muñoz-Martínez… - Nucleic acids …, 2021 - academic.oup.com
The protein kinase ATR plays pivotal roles in DNA repair, cell cycle checkpoint engagement
and DNA replication. Consequently, ATR inhibitors (ATRi) are in clinical development for the …
and DNA replication. Consequently, ATR inhibitors (ATRi) are in clinical development for the …
Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation
MT Dillon, J Guevara, K Mohammed… - The Journal of …, 2024 - Am Soc Clin Investig
BACKGROUND P hase 1 study of ATR i nhibition al o ne or with radiation t herapy
(PATRIOT) was a first-in-human phase I study of the oral ATR (ataxia telangiectasia and …
(PATRIOT) was a first-in-human phase I study of the oral ATR (ataxia telangiectasia and …
Targeting ATR in cancer
E Lecona, O Fernandez-Capetillo - Nature Reviews Cancer, 2018 - nature.com
The chemical treatment of cancer started with the realization that DNA damaging agents
such as mustard gas present notable antitumoural properties. Consequently, early drug …
such as mustard gas present notable antitumoural properties. Consequently, early drug …
The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage–inducing or repair–compromising therapies in preclinical …
AM Wengner, G Siemeister, U Lücking, J Lefranc… - Molecular cancer …, 2020 - AACR
The DNA damage response (DDR) secures the integrity of the genome of eukaryotic cells.
DDR deficiencies can promote tumorigenesis but concurrently may increase dependence …
DDR deficiencies can promote tumorigenesis but concurrently may increase dependence …
[HTML][HTML] Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition
FK Middleton, MJ Patterson, CJ Elstob, S Fordham… - Oncotarget, 2015 - ncbi.nlm.nih.gov
ATRis an attractive target in cancer therapy because it signals replication stress and DNA
lesions for repair and to S/G2 checkpoints. Cancer-specific defects in the DNA damage …
lesions for repair and to S/G2 checkpoints. Cancer-specific defects in the DNA damage …
State-of-the-art strategies for targeting the DNA damage response in cancer
Genomic instability is a key hallmark of cancer that arises owing to defects in the DNA
damage response (DDR) and/or increased replication stress. These alterations promote the …
damage response (DDR) and/or increased replication stress. These alterations promote the …
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
CT Williamson, R Miller, HN Pemberton… - Nature …, 2016 - nature.com
Identifying genetic biomarkers of synthetic lethal drug sensitivity effects provides one
approach to the development of targeted cancer therapies. Mutations in ARID1A represent …
approach to the development of targeted cancer therapies. Mutations in ARID1A represent …